Literature DB >> 25078640

Clinical course and characterisation of lymphangioleiomyomatosis in a Brazilian reference centre.

Bruno Guedes Baldi1, Carolina Salim Gonçalves Freitas, Mariana Sponholz Araujo, Olívia Meira Dias, Daniel Antunes Silva Pereira, Suzana Pinheiro Pimenta, Ronaldo Adib Kairalla, Carlos Roberto Ribeiro Carvalho.   

Abstract

BACKGROUND AND
OBJECTIVE: Lymphangioleiomyomatosis (LAM) is a rare disease that promotes pulmonary cystic destruction and impairs pulmonary function. We aim to describe features and clinical course of LAM patients from Brazil.
METHODS: We described the clinical and functional features, performance in six minute walk test (6MWT), management details, survival and clinical course of 84 LAM patients followed in a Brazilian reference centre.
RESULTS: All subjects were women, the average age at onset of symptoms was 38 years, and the average at diagnosis was 42 years. The major symptoms during the course of the disease were dyspnoea and pneumothorax. The patients experienced impaired quality of life, with worse scores in the physical and emotional domains. The most common abnormalities in pulmonary function tests were an obstructive pattern and reduced diffusion capacity, whereas a quarter of the patients had normal spirometric results. In the 6MWT, although patients had preserved exercise capacity, more than half of the patients had significant desaturation. Hormonal blockage and doxycycline were the most common treatment modalities employed in our patients. The survival probability from diagnosis was 90% at 5 years, whereas the mean annual rate of decline in FEV1 was 60 ± 78 mL.
CONCLUSIONS: Clinical and functional features of the LAM patients from our centre are similar to those from other countries. Our sample showed preserved exercise capacity, with desaturation in the 6MWT, and impaired quality of life. Survival was similar, whereas the annual rate of decline of FEV1 was slightly lower than in recent studies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25078640

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  12 in total

1.  Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.

Authors:  Alexandre Franco Amaral; Martina Rodrigues de Oliveira; Olívia Meira Dias; Fábio Eiji Arimura; Carolina Salim Gonçalves Freitas; Milena Marques Pagliarelli Acencio; Vanessa Adélia de Alvarenga; Ronaldo Adib Kairalla; Carlos Roberto Ribeiro Carvalho; Bruno Guedes Baldi
Journal:  Lung       Date:  2019-01-08       Impact factor: 2.584

Review 2.  Spontaneous pneumothorax in diffuse cystic lung diseases.

Authors:  Joseph Cooley; Yun Chor Gary Lee; Nishant Gupta
Journal:  Curr Opin Pulm Med       Date:  2017-07       Impact factor: 3.155

3.  Experience of Lung Transplantation in Patients with Lymphangioleiomyomatosis at a Brazilian Reference Centre.

Authors:  Bruno Guedes Baldi; Marcos Naoyuki Samano; Silvia Vidal Campos; Martina Rodrigues de Oliveira; José Eduardo Afonso Junior; Rafael Medeiros Carraro; Ricardo Henrique Oliveira Braga Teixeira; Isabela Pasqualini Minguini; Roni Burlina; Eduardo Zinoni Silva Pato; Carlos Roberto Ribeiro Carvalho; André Nathan Costa
Journal:  Lung       Date:  2017-08-19       Impact factor: 2.584

4.  Diffuse cystic lung diseases: differential diagnosis.

Authors:  Bruno Guedes Baldi; Carlos Roberto Ribeiro Carvalho; Olívia Meira Dias; Edson Marchiori; Bruno Hochhegger
Journal:  J Bras Pneumol       Date:  2017 Mar-Apr       Impact factor: 2.624

5.  Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.

Authors:  Francis X McCormack; Nishant Gupta; Geraldine R Finlay; Lisa R Young; Angelo M Taveira-DaSilva; Connie G Glasgow; Wendy K Steagall; Simon R Johnson; Steven A Sahn; Jay H Ryu; Charlie Strange; Kuniaki Seyama; Eugene J Sullivan; Robert M Kotloff; Gregory P Downey; Jeffrey T Chapman; MeiLan K Han; Jeanine M D'Armiento; Yoshikazu Inoue; Elizabeth P Henske; John J Bissler; Thomas V Colby; Brent W Kinder; Kathryn A Wikenheiser-Brokamp; Kevin K Brown; Jean F Cordier; Cristopher Meyer; Vincent Cottin; Jan L Brozek; Karen Smith; Kevin C Wilson; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2016-09-15       Impact factor: 21.405

6.  Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations.

Authors:  Carolina Salim Gonçalves Freitas; Bruno Guedes Baldi; Mariana Sponholz Araújo; Glaucia Itamaro Heiden; Ronaldo Adib Kairalla; Carlos Roberto Ribeiro Carvalho
Journal:  J Bras Pneumol       Date:  2015 May-Jun       Impact factor: 2.624

7.  Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method.

Authors:  Carolina S G Freitas; Bruno G Baldi; Carlos Jardim; Mariana S Araujo; Juliana Barbosa Sobral; Gláucia I Heiden; Ronaldo A Kairalla; Rogério Souza; Carlos R R Carvalho
Journal:  Orphanet J Rare Dis       Date:  2017-04-20       Impact factor: 4.123

8.  Immunohistological features related to functional impairment in lymphangioleiomyomatosis.

Authors:  Ellen Caroline Toledo do Nascimento; Bruno Guedes Baldi; Alessandro Wasum Mariani; Raquel Annoni; Ronaldo Adib Kairalla; Suzana Pinheiro Pimenta; Luiz Fernando Ferraz da Silva; Carlos Roberto Ribeiro Carvalho; Marisa Dolhnikoff
Journal:  Respir Res       Date:  2018-05-08

Review 9.  Lung Diseases Unique to Women.

Authors:  Rachel N Criner; Abdullah Al-Abcha; Allison A Lambert; MeiLan K Han
Journal:  Clin Chest Med       Date:  2021-09       Impact factor: 4.967

10.  Zoledronic acid inhibits TSC2-null cell tumor growth via RhoA/YAP signaling pathway in mouse models of lymphangioleiomyomatosis.

Authors:  Dandan Zhao; Jing Wu; Yinjuan Zhao; Wei Shao; Qi Cheng; Xiaoyan Shao; Xianwen Yuan; Juan Ye; Jianpu Gao; Meiling Jin; Chaojun Li; Xiaolin Chen; Yue Zhao; Bin Xue
Journal:  Cancer Cell Int       Date:  2020-02-10       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.